sharon sanders
Editor-in-Chief & President
A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B
<FORM class=form name=authors1 action=/search/quick method=get><INPUT type=hidden value=yes name=search_medline><INPUT type=hidden value=platform name=search_mode><INPUT type=hidden value=platform+medline name=search_area><INPUT type=hidden value=author name=restrictname_author><INPUT type=hidden value=author name=restricttype_author><INPUT type=hidden name=restrictterm_author><INPUT type=hidden name=restrictdesc_author>Naoki Kawaia
d
, Hideyuki Ikematsuabd, Norio Iwakia, Tetsunari Maedaa, Hideo Kanazawaa, Takashi Kawashimaa, Osame Tanakaa, Satoshi Yamauchia, Kenichi Kawamuraa, Toru Nagaia, Satsuki Horiia, Nobuo Hirotsua, Seizaburo Kashiwagic</FORM>
Accepted 6 September 2007. published online 16 October 2007.
Corrected Proof
Summary
Objective To compare the effectiveness of zanamivir with oseltamivir for influenza A and B.
Methods 1113 patients with influenza A or B were enrolled in the 2006?2007 influenza season. The duration of fever (temperature, ≧37.5?C) and the percentage of patients afebrile at 24 and 48h after the first dose of zanamivir or oseltamivir were calculated. Virus persistence after zanamivir therapy was also evaluated.
Results There were marginally significant differences between the duration of fever after the first dose of zanamivir (31.8?18.4h) and oseltamivir (35.5?23.9h) for influenza A (p<0.05). The duration of fever after starting zanamivir therapy (35.8?22.4h) was significantly shorter than that of oseltamivir (52.7?31.3h) for influenza B (p<0.001). There were no significant differences between influenza A and B in the percentage of patients afebrile at 24 or 48h after the first inhalation of zanamivir. The reisolation rate after zanamivir therapy showed marginally significant differences between influenza A and B (<0.05). By multiple regression analysis, therapy (zanamivir or oseltamivir) was the major determinant affecting the duration of fever for influenza B.
Conclusion Zanamivir therapy is more effective than oseltamivir for the treatment of influenza B infection.
http://www.journalofinfection.com/article/PIIS0163445307007578/abstract
<FORM class=form name=authors1 action=/search/quick method=get><INPUT type=hidden value=yes name=search_medline><INPUT type=hidden value=platform name=search_mode><INPUT type=hidden value=platform+medline name=search_area><INPUT type=hidden value=author name=restrictname_author><INPUT type=hidden value=author name=restricttype_author><INPUT type=hidden name=restrictterm_author><INPUT type=hidden name=restrictdesc_author>Naoki Kawaia
d, Hideyuki Ikematsuabd, Norio Iwakia, Tetsunari Maedaa, Hideo Kanazawaa, Takashi Kawashimaa, Osame Tanakaa, Satoshi Yamauchia, Kenichi Kawamuraa, Toru Nagaia, Satsuki Horiia, Nobuo Hirotsua, Seizaburo Kashiwagic</FORM>Accepted 6 September 2007. published online 16 October 2007.
Corrected Proof
Summary
Objective To compare the effectiveness of zanamivir with oseltamivir for influenza A and B.
Methods 1113 patients with influenza A or B were enrolled in the 2006?2007 influenza season. The duration of fever (temperature, ≧37.5?C) and the percentage of patients afebrile at 24 and 48h after the first dose of zanamivir or oseltamivir were calculated. Virus persistence after zanamivir therapy was also evaluated.
Results There were marginally significant differences between the duration of fever after the first dose of zanamivir (31.8?18.4h) and oseltamivir (35.5?23.9h) for influenza A (p<0.05). The duration of fever after starting zanamivir therapy (35.8?22.4h) was significantly shorter than that of oseltamivir (52.7?31.3h) for influenza B (p<0.001). There were no significant differences between influenza A and B in the percentage of patients afebrile at 24 or 48h after the first inhalation of zanamivir. The reisolation rate after zanamivir therapy showed marginally significant differences between influenza A and B (<0.05). By multiple regression analysis, therapy (zanamivir or oseltamivir) was the major determinant affecting the duration of fever for influenza B.
Conclusion Zanamivir therapy is more effective than oseltamivir for the treatment of influenza B infection.
http://www.journalofinfection.com/article/PIIS0163445307007578/abstract